Rakuten Aspyrian Raises $150 Million in Series C FinancingFunds will support pivotal Phase 3 trial of ASP-1929 in head and neck cancer and additional pipeline expansion to treat other tumor types SAN DIEGO, August 23, 2018-- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy platform, today announced that it has raised $150 million in a Series C financing. This round, as with previous rounds, was led by Hiroshi Mikitani, CEO of Rakuten Inc., a leading global innovation company in e-commerce, communications and fintech, and chairman of Rakuten Aspyrian.